Allarity Therapeutics(ALLR.US)

Last Updated 19:00:00 ET
longbridge loading

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm | ALLR Stock News

StockTitan·
US
ALLR
-2.01%
US
ARKG
+0.30%
US
PBE
-0.19%
StockTitan·
US
ALLR
-2.01%
US
ARKG
+0.30%
US
PBE
-0.19%

Allarity Therapeutics says stenoparib Phase 3 API manufacturing on track for Q3 2026 completion

TradingView·
US
ALLR
-2.01%
US
VHT
-0.01%
US
FBT
-0.22%
TradingView·
US
ALLR
-2.01%
US
VHT
-0.01%
US
FBT
-0.22%

Allarity Therapeutics shares are trading higher after the company announced that its active pharmaceutical ingredient manufacturing campaign for stenoparib is progressing in line with the planned timeline for completion, no later than Q3 of 2026, at its world-class contract development and manufacturing organization.

benzinga_article·
US
ALLR
-2.01%
US
FBT
-0.22%
US
ARKG
+0.30%
benzinga_article·
US
ALLR
-2.01%
US
FBT
-0.22%
US
ARKG
+0.30%

Allarity Therapeutics wins USPTO notice of allowance for stenoparib DRP patent, exclusivity through 2039

TradingView·
US
ALLR
-2.01%
US
XLV
+0.07%
US
BBH
-0.44%
TradingView·
US
ALLR
-2.01%
US
XLV
+0.07%
US
BBH
-0.44%

Allarity Therapeutics publishes AACR 2026 posters on stenoparib showing WNT modulation and DRP-linked survival

TradingView·
US
ALLR
-2.01%
US
BBH
-0.44%
US
FBT
-0.22%
TradingView·
US
ALLR
-2.01%
US
BBH
-0.44%
US
FBT
-0.22%

Allarity's Stenoparib Shows Promise In Colorectal And Ovarian Cancer

nasdaq·
US
ALLR
-2.01%
US
IXJ
-0.18%
US
PBE
-0.19%
nasdaq·
US
ALLR
-2.01%
US
IXJ
-0.18%
US
PBE
-0.19%
© 2026 Longbridge｜Disclaimer